Use of miRNA Sequencing to Reveal Hub miRNAs and the Effect of miR-582-3p/SMAD2 in the Progression of Hepatocellular Carcinoma.
hepatocellular carcinoma
miR-582-3p/SMAD2
miRNA sequencing
migration and invasion
proliferation
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
11
2021
accepted:
04
03
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma is a common tumor with a high fatality rate worldwide, and exploring its pathogenesis and deterioration mechanism is a focus for many researchers. Increasing evidence has shown that miRNAs are involved in the occurrence and progression of a variety of cancers, including hepatocellular carcinoma. Therefore, this study mainly aimed identify key miRNAs related to hepatocellular carcinoma and explore their potential functions and clinical significance. In this study, we performed miRNA sequencing on three pairs of hepatocellular carcinoma tissue samples and screened 26 differentially expressed miRNAs. Then 2 key miRNAs (miR-139-5p and miR-582-3p) were screened by Kaplan-Meier curve analysis, Cox multivariate analysis and qPCR methods. The expression of miR-582-3p was positively correlated with clinicopathological parameters in patients with hepatocellular carcinoma. Subsequently, miRwalk and starbase were used to predict the target genes of key miRNAs, and then the key pairs miR-582-3p/SMAD2 identified by WGCNA, PPI, qPCR and Pearson correlation analysis. Finally, a dual luciferase experiment, the rescue-of-function experiment and qPCR confirmed that miR-582-3p directly targets SMAD2 and regulates the proliferation, migration and invasion of HepG2 cells by targeting SMAD2. At the same time, interference with SMAD2 can influence the effect of miR-582-3p on HepG2 cells. In conclusion, our findings confirm that miR-582-3p is an independent factor for the prognosis of hepatocellular carcinoma patients, and can regulate the progression of hepatocellular carcinoma cells by targeting SMAD2.
Identifiants
pubmed: 35386287
doi: 10.3389/fgene.2022.819553
pii: 819553
pmc: PMC8977860
doi:
Types de publication
Journal Article
Langues
eng
Pagination
819553Informations de copyright
Copyright © 2022 Zhao, Li, Miao, Wei, Dong, Tao, Chen, Pei and Guo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2019 Aug 23;9(1):12329
pubmed: 31444368
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799477
Onco Targets Ther. 2019 Sep 20;12:7739-7748
pubmed: 31571923
Biomed Pharmacother. 2020 Apr;124:109854
pubmed: 31981946
Gut. 2020 Jul;69(7):1309-1321
pubmed: 31727683
Semin Diagn Pathol. 2017 Mar;34(2):153-159
pubmed: 28108047
Aging (Albany NY). 2020 Nov 16;12(22):22759-22775
pubmed: 33202380
Front Genet. 2021 Aug 20;12:709514
pubmed: 34490040
Cell Mol Biol Lett. 2019 Dec 4;24:66
pubmed: 31844417
Biochem Biophys Res Commun. 2020 Jun 25;527(2):393-400
pubmed: 32327260
Biosci Rep. 2020 May 29;40(5):
pubmed: 32285917
Pathol Res Pract. 2019 Oct;215(10):152591
pubmed: 31445716
J Surg Res. 2021 Feb;258:314-323
pubmed: 33317757
J Hematol Oncol. 2020 Feb 7;13(1):12
pubmed: 32033570
J Cell Physiol. 2019 Dec;234(12):23581-23595
pubmed: 31210353
Int J Med Sci. 2021 Aug 25;18(15):3556-3564
pubmed: 34522182
Eur Rev Med Pharmacol Sci. 2020 Oct;24(19):9932-9939
pubmed: 33090397
Theranostics. 2020 Jun 5;10(16):7335-7350
pubmed: 32641995
Clin Chim Acta. 2020 Jan;500:10-19
pubmed: 31604064
Elife. 2015 Jun 30;4:e07091
pubmed: 26126266
Sci Rep. 2018 Jul 26;8(1):11515
pubmed: 30046141
Mol Ther Nucleic Acids. 2019 Jun 7;16:91-104
pubmed: 30852380
Surg Oncol. 2016 Jun;25(2):74-85
pubmed: 27312032
Chem Biol Interact. 2018 Aug 25;292:76-83
pubmed: 30017632
Bioengineered. 2021 Dec;12(2):10771-10781
pubmed: 34793263
J Cell Physiol. 2019 May;234(5):5451-5465
pubmed: 30471116
Int J Mol Sci. 2020 Mar 03;21(5):
pubmed: 32138313
Cancer Cell Int. 2021 May 10;21(1):255
pubmed: 33971879